Opening book details…
About this Medicine article
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials by Hagins, D; Orkin, C; Daar, ES; Mills, A; Brinson, C; DeJesus, E; Post, FA; Morales-Ramirez, J; Thompson, M; Osiyemi, O; Rashbaum, B; Stellbrink, H-J; Martorell, C; Liu, H; Liu, Y-P; Porter, D; Collins, SE; SenGupta, D; Das, M is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Hagins, D; Orkin, C; Daar, ES; Mills, A; Brinson, C; DeJesus, E; Post, FA; Morales-Ramirez, J; Thompson, M; Osiyemi, O; Rashbaum, B; Stellbrink, H-J; Martorell, C; Liu, H; Liu, Y-P; Porter, D; Collins, SE; SenGupta, D; Das, M
- Publisher
- John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 1464-2662)
- Published
- 2018
- Field
- Medicine (Health Sciences)